Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060649670> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2060649670 abstract "OBJECTIVES: Pharmacotherapy can reduce or prevent symptom relapse among schizophrenics, thereby providing long-term benefits. Relapse is common following noncompliance or discontinuation of antipsychotic medication, and dissatisfaction with medication may lead to noncompliance resulting in symptom relapse and increased health care expenditures. We assessed how schizophrenic patients view the use of antipsychotics. METHODS: The Drug Attitude Inventory (DAI), comprised of 10 “yes/no” questions about efficacy, side effects and satisfaction, was used to characterize patients' attitudes and subjective responses to antipsychotic treatment. The DAI was administered to subjects with chronic or subchronic schizophrenia or schizoaffective disorder in a forty-week, double-blind, randomized, parallel-group, flexible-dose study of two regimens of ziprasidone (80 to 120 mg QD or 40 to 80 BID) and one regimen of haloperidol (5 to 20 mg daily). A score was calculated as the sum of the responses to all questionnaire items, and the subsets of six subjective and four attitudinal questions. A categorical linear model was used to analyze the marginal probabilities of favorable responses to the questions. RESULTS: For total, subjective and attitudinal items, DAI scores at baseline were comparable between treatment groups. Overall item response significantly favored ziprasidone at week 40 (p = 0.0016; 7/10 questions showed a higher percentage of positive responses for ziprasidone, and the magnitude of differences per question ranged from +14.2% to −3.7%). This difference was primarily due to positive responses to the subjective questions (p = 0.0006; 4/6 questions showed a higher percentage of positive responses for ziprasidone, and the magnitude of differences per question ranged from +14.2% to −3.2%). CONCLUSIONS: Patients in the ziprasidone groups had a significantly more positive attitude regarding their medication than those in the haloperidol group over 40 weeks of treatment. These findings have implications for greater patient compliance with ziprasidone treatment, which may lead to decreases in relapse rates, hospitalizations, and other health care resource use." @default.
- W2060649670 created "2016-06-24" @default.
- W2060649670 creator A5000160575 @default.
- W2060649670 creator A5026117588 @default.
- W2060649670 creator A5066469649 @default.
- W2060649670 creator A5070458275 @default.
- W2060649670 date "2001-09-01" @default.
- W2060649670 modified "2023-10-05" @default.
- W2060649670 title "PMH4: ASSESSMENT OF PATIENTS' ATTITUDES TOWARD ANTIPSYCHOTIC TREATMENT IN A 40-WEEK RANDOMIZED, CONTROLLED TRIAL" @default.
- W2060649670 doi "https://doi.org/10.1046/j.1524-4733.2001.40202-190.x" @default.
- W2060649670 hasPublicationYear "2001" @default.
- W2060649670 type Work @default.
- W2060649670 sameAs 2060649670 @default.
- W2060649670 citedByCount "0" @default.
- W2060649670 crossrefType "journal-article" @default.
- W2060649670 hasAuthorship W2060649670A5000160575 @default.
- W2060649670 hasAuthorship W2060649670A5026117588 @default.
- W2060649670 hasAuthorship W2060649670A5066469649 @default.
- W2060649670 hasAuthorship W2060649670A5070458275 @default.
- W2060649670 hasBestOaLocation W20606496701 @default.
- W2060649670 hasConcept C118552586 @default.
- W2060649670 hasConcept C126322002 @default.
- W2060649670 hasConcept C15744967 @default.
- W2060649670 hasConcept C168563851 @default.
- W2060649670 hasConcept C2776412080 @default.
- W2060649670 hasConcept C2777270317 @default.
- W2060649670 hasConcept C2778715236 @default.
- W2060649670 hasConcept C2780494398 @default.
- W2060649670 hasConcept C2780948584 @default.
- W2060649670 hasConcept C513476851 @default.
- W2060649670 hasConcept C70410870 @default.
- W2060649670 hasConcept C71924100 @default.
- W2060649670 hasConceptScore W2060649670C118552586 @default.
- W2060649670 hasConceptScore W2060649670C126322002 @default.
- W2060649670 hasConceptScore W2060649670C15744967 @default.
- W2060649670 hasConceptScore W2060649670C168563851 @default.
- W2060649670 hasConceptScore W2060649670C2776412080 @default.
- W2060649670 hasConceptScore W2060649670C2777270317 @default.
- W2060649670 hasConceptScore W2060649670C2778715236 @default.
- W2060649670 hasConceptScore W2060649670C2780494398 @default.
- W2060649670 hasConceptScore W2060649670C2780948584 @default.
- W2060649670 hasConceptScore W2060649670C513476851 @default.
- W2060649670 hasConceptScore W2060649670C70410870 @default.
- W2060649670 hasConceptScore W2060649670C71924100 @default.
- W2060649670 hasLocation W20606496701 @default.
- W2060649670 hasOpenAccess W2060649670 @default.
- W2060649670 hasPrimaryLocation W20606496701 @default.
- W2060649670 hasRelatedWork W1592180368 @default.
- W2060649670 hasRelatedWork W1799577887 @default.
- W2060649670 hasRelatedWork W1862851694 @default.
- W2060649670 hasRelatedWork W2009077931 @default.
- W2060649670 hasRelatedWork W2040552396 @default.
- W2060649670 hasRelatedWork W2055377606 @default.
- W2060649670 hasRelatedWork W2055658079 @default.
- W2060649670 hasRelatedWork W2061781446 @default.
- W2060649670 hasRelatedWork W2087633698 @default.
- W2060649670 hasRelatedWork W2110116096 @default.
- W2060649670 hasRelatedWork W2114627273 @default.
- W2060649670 hasRelatedWork W2154082871 @default.
- W2060649670 hasRelatedWork W2165731251 @default.
- W2060649670 hasRelatedWork W2196425678 @default.
- W2060649670 hasRelatedWork W2387497958 @default.
- W2060649670 hasRelatedWork W2473861279 @default.
- W2060649670 hasRelatedWork W2602295870 @default.
- W2060649670 hasRelatedWork W2810771352 @default.
- W2060649670 hasRelatedWork W3029739401 @default.
- W2060649670 hasRelatedWork W3030018429 @default.
- W2060649670 isParatext "false" @default.
- W2060649670 isRetracted "false" @default.
- W2060649670 magId "2060649670" @default.
- W2060649670 workType "article" @default.